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Optimization of current pain management strategies is necessary in order to reduce medication risks. Promoting patient and
healthcare provider education on pain and pain medications is an essential step in reducing inadequate prescribing behaviors and
adverse events. In an eﬀort to raise awareness on medication safety, the FDA has launched the Safe Use Initiative program. The
program seeks to identify areas with the greatest amount of preventable harm and help promote new methods and practices to
reduce medication risks. Since the establishment of the program, FDA’s Safe Use initiative staﬀ convened a panel of key opinion
leaders throughout the medical community to address pain management in older adults (≥6 5y e a r so fa g e ) .T h ea i mo ft h ee x p e r t
panel was to focus on areas where signiﬁcant risk occurs and where potential interventions will be feasible, implementable, and
lead to substantial impact. The panel suggested one focus could be the use of NSAIDs for pain management in the elderly.
1. Medication Risks
Medication use can result in unwanted adverse reactions
that can cause injury and even death. It was documented
in 2001 that over 4 million people experienced medication
adverse events, which was about 1.5 times the rate observed
in 1995 [1]. The Institute of Medicine has estimated that 1.5
million preventable adverse events occur every year [2]a n d
up to 50% could have been prevented by the modiﬁcation
of prescribing methods [3, 4]. Certain risks cannot be
avoided, and these include unknown risks that do not
manifest during the medication development program and
unpreventable known side eﬀect risks, which result even if
drug administration is executed optimally, that factor in the
risk-beneﬁt evaluation during the regulatory review process
of innovative medications. Though these risks are of great
concern, proper precaution and prescribing methods cannot
circumvent or minimize them [5]. FDA’s Safe Use Initiative
(SUI) focuses on preventable risks that are signiﬁcant and
amenabletoimplementableinterventionsthathavepotential
impact and measurable outcomes.
Identifying,describing,andunderstandingtherootcause
of signiﬁcant preventable risks are essential for reducing
harm from medications. FDA’s SUI describes four main
categories of preventable risks: medication errors, unin-
tended/accidental exposure, intentional misuse/abuse, and
drug quality defects [5]. Medication errors can also be
broken into subcategories: informational errors in prescrib-
ing or by patients/consumers, and procedure and process
type errors. Procedure type errors are frequent, especially
in hospital settings. It was reported that in the ICU
individual patients experienced 1.7 medication errors per
day [6]. A review of the literature focusing on hospital
practices identiﬁed that most medication errors occurred
during administration (53%), but they also occurred during
prescription (17%), preparation (14%), and transcription
(11%) [7]. Though the procedural and process type errors
are of concern, the major focus of FDA’s SUI is informational
errors [5].2 Current Gerontology and Geriatrics Research
2. InformationalErrors:A Major Focus
of the SUI
Informational errors occur during the diﬀerent stages of
the prescribing process and can be a result of the health-
care worker or patient’s limited access to the available
knowledge on a particular medication. Examples of such
events occur when a physician prescribes an NSAID to
a patient with known cardiovascular risk factors; patients
“overdose” or intake greater than the recommended dosage
because approved therapeutic doses did not relieve the
symptoms, or when proper professional monitoring of the
patient while on medication is either not feasible or not
part of the treatment protocol. More attention to education
and awareness among patients, caregivers, and healthcare
professionals could reduce or eliminate these errors, and
methods to promote education will be discussed later.
Since the launch of the SUI in November of 2009, the
FDA met with stakeholders and has held workshops in order
to identify areas of preventable harm and discuss how to
improve current practices to reduce informational errors.
One group of experts convened to address preventable harm
associated with pain medication in older adults and identi-
ﬁed the prescribing practices of NSAIDs as a therapy where
medication errors potentially occur. Treating pain in elderly
patients is a complex task, requiring a tailored and patient
focusedapproachtoprescribing.Becausea“one-size-ﬁts-all”
approach is neither beneﬁcial nor safe for this population,
physicians need to be properly informed about the factors
thatincreasetheoddsofharmfromthisclassofmedications,
risk proﬁles of the diﬀerent NSAIDs, available prescribing
guidelines, and available pain management options. Areas of
concern related to NSAID use in the elderly are discussed in
order to promote awareness of where changes in the current
practice might have an impact.
3. Complexity of the Elderly in
Pain Management
The elderly population is normally classiﬁed as being greater
than 65 years of age. The information provided by the
Administration of Aging estimates that by 2030 there will be
72.1 million people over the age of 65 in the United States,
which is approximately double what the population was in
2000 [8]. Better lifestyles through proper dieting/exercise
and more eﬃcient disease management therapies (e.g.,
surgical/pharmaceuticaltechnology)havecontributedtothis
population rise. Prescribing pain medications within the
elderly population requires the skill of a very knowledgeable
physician to navigate through the numerous variables (e.g.,
physiologic changes, comorbid conditions, multiple medi-
cations) that make the elderly population a heterogeneous
and complex population to treat [9]. Additionally, the lack of
evidence-based practices, training, awareness, and thorough
understanding of these variables increase the risk of pain
medication safety events in an already complex patient.
An initial task during one of the workshops was to
identify factors impacting the safe use of pain medications
Table 1: Factors that aﬀect prescribing methods in elderly patients.
General factors
(1) “One-size-ﬁts-all” approach not applicable
(a) All geriatric patients / =
(2) Physiology
(a) Renal decline
(b) Hepatic decline
(c) Body muscle/fat composition change
(3) Perception of pain varies
(4) Cognitive impairment
(a) Medication literacy decline
(b) Confusion about what, when, and how much
medication to take
(5) Comorbidities
(a) Interactions with medications
(b) Require multiple medications
(6) Polypharmacy
(a) Confusion about what, when, and how much
medication to take
(b) Overdosing
(c) Drug-drug interactions
(7) Age-related factors interactions with medication
(a) Increased susceptibility
(b) Atypical presentation
(c) Delayed/lack of detection
(8) Evidence-based practices
(a) Lack of a roadmap to optimally manage pain
(9) Multiplicity of providers and lack of team approach to
managing health conditions in the elderly
(a) Multiple physicians prescribing
(b) Pharmacists
(c) Self/consumer
(d) Insurance companies
(10) Cost/coverage of medications
in the elderly (Table 1). The pathophysiologic proﬁle of
older adults signiﬁcantly changes with age. Decline in organ
function, particularly the renal and hepatic functions, which
are critical in the clearance of ingested substances, dictates
the pharmacokinetic properties of many drugs [10]. In addi-
tion, aging patients can experience changes in body fat and
water composition [10, 11]. These changes alter the tissue
and plasma distributions of many lipophilic and hydrophilic
drugs in ways that predispose patients to adverse eﬀects [10].
Decline in the cognitive function is also an area of concern
with aging adults [10]. Impairment of cognitive function can
lower medication literacy [12, 13], which has been associated
with a decrease in the likelihood of reading prescription
leaﬂets or additional medication information [14, 15], a
reduction in medication reconciliation (agreement between
physicians and patients on what medications are currently
being used) [16], patients misinterpreting dosage directionsCurrent Gerontology and Geriatrics Research 3
ondruglabels[17],andfailuretoadheretoverbalcounseling
by physicians [18].
Physiologic changes that occur with aging increase the
incidence and prevalence of many diseases which directly
increases the risk of developing a drug-related disease
interaction. In 2009, the Administration of Aging reported
that almost all of Medicare beneﬁciaries had at least one
morbid condition while approximately 24% had greaterthan
4 morbid conditions [20]. Common conditions among the
elderlypopulation include diagnosedarthritis, hypertension,
heart disease, cancer, diabetes, and sinusitis [20]. Comorbid-
ity is associated with polypharmacy, a phenomena where a
single person may be prescribed multiple medications from
diﬀerent doctors or by self-prescribing over-the-counter
medications(OTCs)foreachmedicalconditionpresent[21].
A general list of medications that many elderly may be
on include cardiovascular drugs (thiazide diuretics, (ACE)
inhibitors, beta-blockers); antidiabetic drugs (sulfonylureas,
thiazolidinediones, and metformin); ﬂuticasone/salmeterol,
tiotropium, albuterol, bronchodilators and steroid inhaler,
nonsedating antihistamines, and steroid nasal sprays [22].
Depending on the deﬁnition of polypharmacy or type of
study conducted, anywhere from 13 to 92% of the geriatric
population is on more than one drug [22]. Other studies
indicate 80% of patients over the age of 65 years have at
least one chronic condition while 50% have more than one;
this same group uses between 2 to 6 prescribed medications
and 1 to 3.4 nonprescription medications on a regular
basis [23, 24]. As the number of medications that are
taken increases, the risk of adverse drug reactions increases
[24]. Patients taking two drugs concurrently have a 13%
risk of adverse drug interactions, those taking four drugs
have a risk of 38%, and those taking seven or more drugs
h a v ear i s ko fu pt o8 2 %[ 25]. Another issue that arises
from polypharmacy is that it becomes diﬃcult for multiple
physicians, pharmacists, and even the patients themselves to
keep track of all the medications, thus increasing the odds of
drug-drug interactions [26].
Understanding, preventing, monitoring, and treating
adverse events in the elderly are diﬃcult tasks. Whether
it is just aging in itself and/or the physiologic changes
associated with aging, the elderly population is at increased
riskofexperiencingmoreadverseevents[27–29].Inthe2011
DAWN report, it was estimated that in 2008 more than 31%
of people 65 and older were hospitalized due to a medication
adverse event and that patients older than 50 represented
51.5% of all hospitalizations related to adverse events [30].
The challenge is that often it is diﬃcult to discern between
the aging process itself, associated comorbidities, and an
adverse event that is secondary to drug therapies. Some
symptoms such as lethargy, confusion, lightheadedness, falls,
constipation, and depression that are observed as side eﬀects
of a number of medications are often experienced in elderly
patients not on any particular drug [31, 32]. In the dominant
climate of evidence-based medicine, there is a general unease
regarding how medications aﬀect the elderly population.
Even though enrollment of older adults in clinical trials
has been occurring since the 1980s, the representation of
the “complex” elderly population is limited [33], rendering
optimal evaluation of the beneﬁts and risks of any med-
ication to be a challenging task. Complex elderly people
are typically aged 75 and older, have multiple concomitant
illnesses, take multiple medications, and have some level of
functional decline, cognitive impairment, and limited social
support [33]. In addition to homogenous selection process
among the elderly for the clinical trials, most clinical trials
also require “homogenous” treatment plans. Therefore, it is
also hard to evaluate adverse events associated with drug-
drug interactions.
4.PhysicianBarriersinNSAID
Pain Management
The nonsteroidal anti-inﬂammatory drugs have been a
mainstay option for chronic pain management for many
years. Adverse side eﬀects associated with NSAIDs including
gastrointestinal, cardiovascular, renal, and hematological,
have been known for a long time. However, introduction of
new drugs into the marketplace and the continuous stream
of new research data have recently called into question the
use and prescribing guidelines of NSAIDs in the elderly,
especially “complex” elderly patients [34, 35].
The workshop assembled by FDA’s SUI wanted to deter-
mine areas in the prescribing process of NSAIDs that may
lead to medication errors and potential injury. Optimal pain
management and an increased risk of harm may occur due
to “physician barriers”, factors that may hinder or prevent
a physician from adequately and safely treating a patient
(Table 2). Prescribing NSAIDs to any patient, especially the
elderly, requires knowledge of individual patient risk factors,
the ability to assess the beneﬁts and risks of the NSAID,
and the responsibility for educating patients and monitoring
for eﬀectiveness and side eﬀects of the prescribed NSAID. A
recent report demonstrated that more than 50% of patients
were not properly informed by a physician or pharmacist
on the side eﬀects associated with Rx or OTC NSAIDs [36].
Recent data show that the majority of physicians studied
are unaware of potential complications associated with
cardiovascular [37] and gastrointestinal systems [38, 39].
NSAIDguidelineshavebeenestablishedtoincreasephysician
awareness of the complications associated with NSAID use;
however, some physicians either do not recognize or do not
adhere to such guidelines [40]. A recent survey of physicians
identiﬁed six major barriers that aﬀected their use of estab-
lished NSAID guidelines [41]. The barriers mentioned were
as follows: lack of familiarity with the guidelines, perceived
limited validity of the guidelines, limited applicability of the
guidelines to speciﬁc patient populations, clinical inertia,
anecdotal experiences, and clinical heuristics [41]. The lack
of familiarity was attributed to the overwhelming number of
publishedmedicalguidelinesanddiﬃcultiesinkeepingupto
date with new recommendations. In support of this, a search
of the literature identiﬁed more than 20 diﬀerent guidelines
that mention NSAIDs and the elderly in addition to other
highly acclaimed medication risk factor guidelines or tools
(Table 3).4 Current Gerontology and Geriatrics Research
Table 2: Barriers created during NSAID therapy.
Physician barriers Patient barriers
(1) Limited awareness of or failure to adhere to available
NSAIDs Guidelines
(1) Barriers to patient education regarding the proper use of
medications
(a) Too many guidelines (a) Power of TV ads on decision for what medications to
take
(b) Confusion about which guidelines are applicable to
what segment of the elderly population
(b) Limited awareness of the risks associated with
medications
(2) Barriers to using available and up-to-date knowledge on
NSAIDs
(2) Failure to objectively, properly, and safely alleviate pain
(a) Prevalence and intensity of pain sometimes clouds
patients’ reasoning and leads to unsafe medication
intake behavior
(3) Inability of primary health care providers to pursue
education/training on how to adjust some of the medical
practice aspects to the geriatric population
(3) Economic factors
(a) Cost of copayments sometimes deter from seeking
professional and appropriate prescriptions
(4) Barriers to optimally manage patient’s pain which leads
the patient to seek other sources of alleviating it
(4) Misperception about the safety of OTC medications
(a) Risk of overdosing, drug-drug interactions, and
chronic use
(b) Failure to recognize or legitimize the tell-tale signs of
adverse events
(5) Limited physician-patient interchange regarding proper
use and what to expect
(5) Limited awareness of NSAID sources
(a) OTC
(b) Prescription
(6) Absence of systematic screening, monitoring, and
educational procedures for prevention
(a) Identify patients at high risk of renal impairment, GI
bleed, cardiovascular side eﬀects, and other AEs and
manage them appropriately
(b) Ask/document OTC use including NSAIDs and
dietary supplements
(c) Warn patients about speciﬁc NSAID serious adverse
events
(d) Make patient aware of medications that interact with
NSAIDs
(e) Educate patient about the risk of long-term use of
NSAIDs
(i) Ex. patients at high risk of CVD
(f) Prescribe prophylactic measures
(i) Ex. proton pump inhibitors
(7) Barriers to the use of new technological tools to improve
prescribing
(8) Limited awareness of and evidence-based practice for
nonpharmacologic approaches to pain reduction
In addition to education on NSAIDs, prevention and
monitoring mechanisms should also be followed or adhered
to appropriately in order to provide additional levels of
protection for the patients. For example, in a survey of
615 elderly patients in an outpatient or old age/nursing
home setting for the coadministration of an NSAID with a
prophylactic product to protect against gastrointestinal side
eﬀects, 65.3%, 76.2%, and 42.6% failed to receive necessary
prophylaxis in the outpatient, old age, and nursing home
settings, respectively [42], even though treatment for such
side eﬀects are documented in well-established guidelines
put forth by the American Geriatric Society [43]. Another
safeguard is the task of proper documentation of medical
history. A large French study known as CADEUS (COX-2
inhibitors and NSAIDs: description of users) showed that
there was a failure on the part of physicians to document and
keep patient records. More than 50% of the medical histories
described by the patient were not recorded by the physician
[44]. OTC drugs and dietary supplements are often believed
to be risk-free [45] and are not asked about or documented.Current Gerontology and Geriatrics Research 5
Table 3: List of current guidelines containing NSAIDs and/or eld-
erly.
(1) Agency for Healthcare Research and Quality (AHRQ)
(2) American Academy of Family Physicians
(3) American Academy of Orthopaedic Surgeons
(4) American College of Gastroenterology
(5) American College of Physicians
(6) American College of Rheumatology
(7) American Geriatrics Society
(8) American Heart Association
(9) American Pain Society
(10) American Society of Anesthesiologists
(11) Institute for Clinical Systems Improvement
(12) Institute for Clinical Systems Improvement
(13) National Headache Foundation
(14) National Kidney Foundation
(15) Osteoarthritis Research Society International (OARSI)
(16) US Headache Consortium
(17) Beers List∗
(18) HEIDIS∗
(19) STOPP and START∗
(20) McLeod∗
(21) IPET∗
(22) ACOVE∗
∗Tools to identify potential inappropriate medications.
Prescribers need to be aware of the possibility of over-
dosing on NSAIDs that might result from prescribing and/or
taking OTC medications that contain the same active NSAID
ingredient. A meta-analysis of data from case-control studies
revealed that the odds ratio (reference point is nonuse of
NSAIDs) for experiencing a serious GI complication was 4.9
inpatientstakingasingleNSAID,10.7inpatientstakingtwo,
and 60.0 in patients taking three NSAIDs simultaneously
[46].Table 4 identiﬁessomeofthecommonprescriptionand
OTC NSAID medications in hopes of promoting awareness.
In addition, combination of certain medications or herbal
additives with prescribed or OTC NSAIDs may intensify or
mask the side eﬀects associated with NSAIDs; for example,
corticosteroids [47], ginkgo biloba [48, 49], warfarin [50],
and alcohol [51] can increase the severity of gastrointestinal
bleeding or peptic ulcers.
5. Patient Barriers in NSAID Pain Management
There are also “patient barriers” that might limit the eﬀec-
tiveness of pain treatment or predispose to greater risk of
adverse eﬀects (Table 2). Before taking any type of medica-
tion, patients should be fully aware of the risks involved;
however, data suggest that current patient education on
NSAIDs, in particular side eﬀects and how to manage them,
is not adequate [36, 52, 53]. Another study that analyzed 807
NSAID users reported that 54% did not know the side eﬀects
associated with NSAIDs; additionally, it reported that 33%
believed prescription NSAIDs were safer, 32% believed OTC
NSAIDsweresafer,20%believedtherewasnodiﬀerence,and
15% did not know. Sixty percent and 29% of exclusive OTC
NSAID users were neither aware or did not believe they were
at risk of side eﬀects from NSAIDs, respectively [54].
In addition to being ill-informed on the side eﬀects of
taking a single NSAID, patients are also unaware of the
consequences of taking multiple NSAIDs or taking NSAIDs
for long periods of time. A recent report analyzed responses
from rheumatologic pain patients on their knowledge of
prescribed NSAID and OTC NSAID risks [55]. Forty-nine
percent knew that taking multiple NSAIDs increased the
risks of side eﬀects, 41% were uncertain, and 10% did
not believe the claim [55]. Some of the reasons for taking
multiple doses of NSAIDs include seeking more or faster
relief, experiencing no relief with the recommended dose,
o rar e s u l to fd o c t o r ’ ss u g g e s t i o n[ 54]. In addition, patients
are sometimes unaware of or misinformed by practitioners
about other medications that contain NSAIDs, like cold or
ﬂu OTC medicines [54]. In order to promote awareness,
some of the common medications containing NSAIDs are
listed in Table 4.
6. Interventions
In addition to identifying areas of concern during NSAID
treatment of the elderly, the workshop participants brain-
stormed possible ways to address some of the issues
mentioned throughout this paper. These interventions are
solely presented as suggestions and are meant to stimulate
further discussion within the health care community. For
simplicity, the information presented throughout this paper
can be divided into 4 categories: (1) health care provider
training/knowledge/education/awareness; (2) patient educa-
tion/awareness; (3) optimization and use of standardized
processes/mechanisms/tools; (4) communication between
the healthcare entities involved and care coordination
(Figure 1). Working on and improving these areas can be
an excellent opportunity to mitigate preventable adverse side
eﬀects. In order to improve health care provider education,
some ideas include licensure requirements, specialty training
in geriatric pain management, and incorporation of training
in medical schools. Currently there are many guidelines
that outline prescribing methods for NSAIDs in the elderly
(Table 3). However, healthcare providers can become over-
whelmed and confused regarding which guidelines are more
appropriate. A suggestion to correct for this would be to
simplify and present one unifying document either in a
written and/or visual form. Suggestions to improve patient
education and awareness include standardizing patient
education materials and/or incorporating new technology
to increase information ﬂow to and assimilation by the
elderly. Underutilized technology may include visual aids,
which can take the form of videos played in doctor’s oﬃce
waiting rooms, podcasts for computers or cell phones, even
YouTube videos. Other suggestions may be to incentivize
communication between healthcare providers and patients,
for example, in primary care oﬃces where nurses take on a6 Current Gerontology and Geriatrics Research
Table 4: List of Rx and OTC NSAIDs [19]: ∗some items may no longer be currently marketed in the US and current list may not be
exhaustive. Data is from 2009.
Common medications containing aspirin
Alka Seltzer Excedrin Extra-Strength Analgesic Panasal
Anacin Tablets and Caplets Percodan Tablets
Arthritis Pain Formulav Excedrin Migraine Persistan
Arthritis Foundation Pain Reliever Fiogesic Pravigard
ASA Enseals Fiorgen PF Rhinocaps
Arthritis Strength Buﬀerin Fiorinal (most formulations) Robaxisal Tablets
Analgesic Caplets Fiortal Sine-Oﬀ Sinus Medicine Tablets-
ASA Suppositories Gelpirin Aspirin Formula
Ascriptin Genprin Roxiprim
A/D Gensan Saleto
Aspergum Heartline Salocol
Asprimox Headrin Sodol
Axotal Isollyl Soma Compound Tablets
Azdone Lanoprinal Soma Compound with
Bayer (most formulations) Lortab ASA Tablets Codeine Tablets
BC Powder and Cold Magnaprin St. Joseph Adult Chewable Aspirin
Buﬀerin (most formulations) Maximum Strength Arthritis Pain Supac
Buﬀe t sI I F o r m u l aB yt h eM a k e r so f S u p r i n
Buﬀex Anacin Analgesic Synalgos -DC Capsules
Cama Arthritis Pain Reliever Marnal Tenol-Plus
COPE Micrainin Trigesic
Dasin Midol Tri-pain
Darvon Compound 65 Momentum Talwin Compound
Dolprin no. 3 Norgesic Forte (most formulations) UN-aspirin
Easprin Aspirin Norwich Regular Strength Ursinus
Ecotrin (most formulations) Aspirin Vanquish Analgesic Caplets
Empirin Aspirin (most formulations) PAC Analgesic Tablets Wesprin Buﬀered
Epromate Pain Reliever Tablets Zee-Seltzer
Equagesic Tablets Orphengesic ZORprin
Equazine Painaid
Common medications containing an NSAID
Actron Caplets Flurbiprofen Motrin IB
Advil Genpril Nabumetone
Advil Migraine Ibuprin Nalfon
Advil Cold and Sinus Ibuprofen Naproxen
Aleve Indomethacin Naprosyn
Altran Indocin Nuprin
Anaprox DS Ketoprofen Orudis KT
Ansaid Ketorolac Oxaprozin
Arthrotec Lodine PediaCare Fever
Bayer Select Pain Relief Meclofenamate Piroxicam
Formula Caplets Mefenamic Acid Ponstel
Children’s Motrin Meloxicam Relafen
ClinorilV Menadol Saleto 200
Daypro Midol IB Sulindac
Diclofenac Mobic Toradol
Etodolac Voltaren
Feldene
FenoprofenCurrent Gerontology and Geriatrics Research 7
present in written and visual form
Standardization of existing
processes and tools
Patient education and
awareness Communication b/w
health care entities
(ii) Licensure requirements
(iii) Training across the spectrum
(iv) Incentive for training
(v) Cross-functional training
(vii) Training in medical school
(i) Promote physician interaction
(i) Standarize patient education
Ex. AARP, APF, APHA
Ex. cell phone apps
individualized, easy, not time consuming
(ii) Patient medical history checklist
incorporate activities of daily living
(i) Simplify guidelines
(i) Create a ﬂexible therapeutic decision support model
(ii) Change information ﬂow to elderly
speciﬁc for NSAIDs use
(vi) Whole-team training
Health care provider education
(ii) Create a universal guideline
Figure 1: Interventions for optimizing prescribing practices of NSAIDs in the elderly.
large role disseminating medical information. Finally, open-
ing up the lines of communication between all healthcare
entities would allow for a more patient-focused treatment.
Additional intervention ideas included establishment of a
therapeutic decision support model or even a required
checklist designed to cover all points of a patient’s medical
history.
7. Conclusion
Medication errors can have a serious public health impact
andbecostly.TheSafeUseInitiative(SUI)isanonregulatory
eﬀort within FDA; one of its focus points is to identify
areas where medication errors can be prevented. Through
collaboration with key stakeholders, the SUI hopes to raise
awarenessoftheseissuesandhelpthehealthcarecommunity
make changes. As a result of the combined eﬀorts of SUI and
its partners, a number of key areas were identiﬁed as worth
addressing in order to optimize pain therapy. Healthcare
providereducationonNSAIDuseisnecessaryfortheprotec-
tion of a patient’s wellbeing. Improving physician (and other
healthcare providers) adherence to NSAID guidelines and
enhancing understanding of the pharmacology of NSAIDs
in the geriatric population is an essential step to reducing
medication errors. Finding new and innovative ways to
promote education and awareness should be a task which the
entire medical community addresses.
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